Online inquiry

IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2294MR)

This product GTTS-WQ2294MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2294MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11265MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ10437MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ4117MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI-505
GTTS-WQ7321MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ6861MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DX-2930
GTTS-WQ7190MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ14480MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ7226MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW